OTTMUSG00000011070 Inhibitors
Chemical inhibitors of OTTMUSP00000011071 employ various mechanisms to disrupt the protein's function within cellular signaling pathways. Wortmannin and LY294002 are both potent inhibitors of the phosphoinositide 3-kinases (PI3K), a family of enzymes involved in cellular functions such as cell growth, proliferation, differentiation, motility, and survival. By inhibiting PI3K, these chemicals directly impede the PI3K/AKT pathway, which is essential for the activation and regulation of OTTMUSP00000011071. Further along this pathway, Rapamycin exerts its inhibitory effect by binding to FKBP12, which then targets mTOR, a central protein in the same pathway, leading to a reduction in protein synthesis and cell growth signals that are necessary for OTTMUSP00000011071 function.
In addition to the PI3K/AKT/mTOR pathway, OTTMUSP00000011071 function can be inhibited by interfering with the MAPK pathway. PD98059 and U0126 are selective inhibitors of MEK, which is upstream of ERK in this pathway. Inhibition of MEK prevents the activation of ERK, thus blocking the MAPK/ERK signaling cascade that could be crucial for OTTMUSP00000011071. Similarly, SB203580 and SP600125 target other MAPK pathway components, specifically p38 MAP kinase and c-Jun N-terminal kinase (JNK), respectively. By inhibiting these kinases, the associated stress response, and JNK signaling, which may be required for OTTMUSP00000011071 functionality, are disrupted. PP2, a selective inhibitor of Src family tyrosine kinases, and Dasatinib, which targets both Src family kinases and BCR-ABL, prevent tyrosine phosphorylation events that are essential for OTTMUSP00000011071 activity. Erlotinib and Lapatinib inhibit the EGFR and HER2 tyrosine kinase domains, respectively, blocking critical signaling pathways involving these receptors that may be necessary for the activity of OTTMUSP00000011071. Lastly, Sorafenib targets multiple kinases, particularly those involved in the VEGFR and PDGFR signaling pathways, thereby blocking the signaling required for processes that OTTMUSP00000011071 could be a part of.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), which are involved in various signaling pathways, including those regulating cell growth and survival. By inhibiting PI3K, Wortmannin can inhibit OTTMUSG00000011070 by disrupting downstream signals necessary for its function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another PI3K inhibitor that prevents the kinase activity of PI3K, leading to a disruption of the PI3K/AKT pathway. As this pathway is crucial for many cellular processes, LY294002 can inhibit OTTMUSG00000011070 by halting the cellular signals it depends on. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin binds to FKBP12 and together they inhibit mTOR, a key protein in the PI3K/AKT/mTOR pathway. Inhibition of mTOR can dampen the signaling required for protein synthesis and cell growth, thereby inhibiting OTTMUSG00000011070 by reducing its functional activity in the cell. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which acts upstream of ERK in the MAPK pathway. By inhibiting MEK, PD98059 can inhibit OTTMUSG00000011070 by preventing the activation of the ERK pathway which might be essential for the protein's functional activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor that prevents the activation of MAPK/ERK kinase, thereby inhibiting the MAPK/ERK pathway. This can lead to inhibition of OTTMUSG00000011070 by halting the signaling events that rely on this pathway for protein function. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 specifically inhibits p38 MAP kinase, which is involved in inflammatory responses and stress-induced signaling. By inhibiting p38 MAP kinase, SB203580 can inhibit OTTMUSG00000011070 by disrupting associated stress response signaling pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of c-Jun N-terminal kinase (JNK), which is part of the MAPK pathway. Inhibition of JNK can lead to inhibition of OTTMUSG00000011070 by blocking the JNK signaling that may be required for the protein's functional output. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is a selective inhibitor of Src family tyrosine kinases. By inhibiting Src kinases, PP2 can inhibit OTTMUSG00000011070 by preventing tyrosine phosphorylation events necessary for its activity. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Dasatinib is a multi-targeted inhibitor, including Src family kinases and BCR-ABL. By inhibiting these kinases, Dasatinib can inhibit OTTMUSG00000011070 by interrupting the kinase-dependent signaling pathways critical for its function. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR inhibitor that blocks tyrosine kinase activity. By targeting EGFR, Erlotinib can inhibit OTTMUSG00000011070 by disrupting the EGFR signaling pathways that may be essential for the protein's activity. | ||||||